Relay Therapeutics Shares Reach New 52-Week High

Biotech stock surges as analysts debate whether the rally has more room to run

Apr. 17, 2026 at 8:34am

Got story updates? Submit your updates here. ›

An extreme close-up of a complex array of metallic gears and machinery, representing the intricate financial systems and institutional infrastructure driving the surge in Relay Therapeutics' stock price.Relay Therapeutics' stock price reaches new heights, reflecting growing investor confidence in the biotech firm's innovative drug discovery platform.Cambridge Today

Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage biotech company focused on precision cancer therapies, reached a new 52-week high of $15.89 on Wednesday. The stock closed at $14.75, up 4.3% on the day, with heavy trading volume of over 4 million shares.

Why it matters

Relay Therapeutics' stock price surge reflects growing investor optimism about the company's pipeline of drug candidates that leverage advanced computational modeling and structural biology to target dynamic protein motion. However, analysts are divided on whether the current valuation fully reflects the company's future potential.

The details

Several research firms have weighed in on Relay Therapeutics in recent weeks. Weiss Ratings maintained a 'sell (d-)' rating, while firms like Citizens JMP, HC Wainwright, and Guggenheim all increased their price targets, with Guggenheim raising its target to $22 and reiterating a 'buy' rating. The company also reported better-than-expected Q4 2025 results in late February, with revenue of $7 million exceeding analyst estimates.

  • Relay Therapeutics shares reached a new 52-week high of $15.89 on Wednesday, April 17, 2026.
  • The company reported Q4 2025 financial results on February 26, 2026.

The players

Relay Therapeutics, Inc.

A clinical-stage biotechnology company focused on developing precision therapies for oncology, leveraging computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates.

Weiss Ratings

A research firm that maintained a 'sell (d-)' rating on Relay Therapeutics' stock.

Citizens JMP

A research firm that increased its price target on Relay Therapeutics' stock to $17 and maintained a 'market outperform' rating.

HC Wainwright

A research firm that increased its price target on Relay Therapeutics' stock to $19 and maintained a 'buy' rating.

Guggenheim

A research firm that increased its price target on Relay Therapeutics' stock to $22 and maintained a 'buy' rating.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

The takeaway

Relay Therapeutics' stock surge reflects growing investor optimism about the company's innovative approach to drug discovery, but analysts remain divided on whether the current valuation fully reflects the company's long-term potential.